Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the ...

CAR2119’s single-infusion approach offers cost and compliance advantages, though its competitors maintain strong commercial ...

Integrating a computational workflow that leverages multi-omics data with a proprietary, humanized in vivo screening platform ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Early research has identified several antigens that could ...

October 12, 2025 - PORTERVILLE, Calif. — A cutting-edge cancer treatment that reprograms the body’s own immune cells saved a ...

CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company, announces that Chris Ehrlich, Chief Executive Officer will participate in a ...